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OBJECTIVE—Differentiation of human embryonic stem (hES)
cells to fully developed cell types holds great therapeutic prom-
ise. Despite signiﬁcant progress, the conversion of hES cells to
stable, fully differentiated endocrine cells that exhibit physiolog-
ically regulated hormone secretion has not yet been achieved.
Here we describe an efﬁcient differentiation protocol for the in
vitro conversion of hES cells to functional glucagon-producing -
cells.
RESEARCH DESIGN AND METHODS—Using a combination
of small molecule screening and empirical testing, we developed
a six-stage differentiation protocol for creating functional -cells.
An extensive in vitro and in vivo characterization of the differ-
entiated cells was performed.
RESULTS—A high rate of synaptophysin expression (75%)
and robust expression of glucagon and the -cell transcription
factor ARX was achieved. After a transient polyhormonal state in
which cells coexpress glucagon and insulin, maturation in vitro
or in vivo resulted in depletion of insulin and other -cell
markers with concomitant enrichment of -cell markers. After
transplantation, these cells secreted fully processed, biologically
active glucagon in response to physiologic stimuli including
prolonged fasting and amino acid challenge. Moreover, glucagon
release from transplanted cells was sufﬁcient to reduce demand
for pancreatic glucagon, resulting in a signiﬁcant decrease in
pancreatic -cell mass.
CONCLUSIONS—These results indicate that fully differentiated
pancreatic endocrine cells can be created via stepwise differen-
tiation of hES cells. These cells may serve as a useful screening
tool for the identiﬁcation of compounds that modulate glucagon
secretion as well as those that promote the transdifferentiation of
-cells to -cells. Diabetes 60:239–247, 2011
H
uman embryonic stem (hES) cells hold great
potential for the development of replacement
therapies for conditions including heart dis-
ease, spinal cord injury, and diabetes. With the
recent FDA approval of the ﬁrst U.S.-based clinical trial for
the use of cells derived from hES cells (1), there is
renewed optimism that other stem cell–based therapies
may soon be developed and tested clinically. Treatment of
type 1 diabetes with cadaveric human islets has been
promising, suggesting that a cell-based therapy for this
disease may be possible given sufﬁcient availability of
transplant material. hES cells can be efﬁciently differenti-
ated to deﬁnitive endoderm (2,3) and further to endocrine-
like polyhormonal cells that are capable of hormone
secretion in response to some physiologic and pharmaco-
logic stimuli (4–6). However, the formation of mature,
single hormone-expressing endocrine cells in culture re-
mains a major hurdle. Recent efforts have been focused on
the maturation of partially differentiated cells toward
-cells in vivo after transplantation into model animals
(7,8); however, the clinical use of partially differentiated
cells may present an unacceptable risk of tumor forma-
tion. We therefore sought to develop a protocol for the in
vitro differentiation of a functional, terminally differenti-
ated endocrine cell type from hES cells. In pursuing our
goal of ultimately developing a scalable protocol to pro-
duce -cells, we established a method to convert hES cells
to functional glucagon-expressing cells that resemble ma-
ture pancreatic -cells.
RESEARCH DESIGN AND METHODS
Differentiation of hES cells. The H1 hES cell line was obtained from WiCell
Research Institute (Madison, WI), and cultured according to instructions
provided by the source institute. Brieﬂy, cells were cultured on 1:30 diluted,
growth factor-reduced Matrigel- (Invitrogen; Carlsbad, CA) coated plates in
mouse embryonic ﬁbroblast (MEF)-conditioned media as previously de-
scribed (9). When 80% conﬂuent (5–7 days after plating), hES cells were
treated with 1 mg/ml Dispase (Invitrogen) for 5 min and then gently scraped
off the surface using a 5-ml pipette. Cells were spun at 900 rpm for 3 min, and
the pellet was resuspended and replated at a 1:3 to 1:4 ratio of hES cells in
MEF-conditioned media supplemented with 16 ng/ml of ﬁbroblast growth
factor 2 (FGF2) (R&D Systems; Minneapolis, MN). Details of stage-speciﬁc
treatments are described in the supplementary data in the online appendix
available at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0573/DC1.
Human islets. Human islets were obtained from the Irving K. Barber Human
Islet Isolation Laboratory (Vancouver, BC) and were maintained in Final Wash
Media (Mediatech, Inc., Herndon, VA). For dithizone staining, islets were
washed with PBS(-), then incubated in a ﬁlter-sterilized 78 mol/l dithizone
(Sigma-Aldrich) solution in DMSO for 1 h. Islets were then washed with
Dulbecco’s modiﬁed Eagle’s medium/F12 media to remove excess dithizone
and examined under a light microscope.
Quantitative RT-PCR. Total RNA was extracted with the RNeasy Mini Kit
(Qiagen; Valencia, CA) and reverse-transcribed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to
the manufacturer’s instructions. The cDNA was ampliﬁed by PCR using
Taqman Universal Master Mix and Taqman Gene Expression Assays (see
supplementary Table 2), which were preloaded onto custom Taqman Arrays
(Applied Biosystems). Data were analyzed using Sequence Detection Software
(Applied Biosystems) and normalized to undifferentiated ES cells using the
Ct method.
Insulin, glucagon, and DNA content. Cells were lysed by suspension in
Tris-EDTA (pH 7.4) followed by sonication until cell membranes were
dispersed. DNA content was determined using the Quant-IT Picogreen kit
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Insulin and Glucagon ELISA, respectively (Alpco Diagnostics; Salem, NH).
Flow cytometry. Differentiated cells were released into single-cell suspen-
sions by incubation in TrypLE Express (Invitrogen), ﬁxed, and stained using
antibodies directed against intracellular proteins as indicated in the text. A
detailed description of staining can be found in the online supplementary data.
Immunocytochemistry. Isolated human islets and stage 6 differentiated hES
cell clusters were ﬁxed in 4% paraformaldehyde (PFA) overnight at 4°C, then
embedded in a 1% agarose in PBS gel before being parafﬁn embedded and
sectioned for immunostaining. Graft-bearing kidneys and pancreata were
ﬁxed in 4% PFA overnight at 4°C before being parafﬁn embedded and
sectioned. All sections were cut at a thickness of 5 m. Staining procedures
and antibodies used are detailed in the online supplementary data.
-Cell mass quantiﬁcation. After DAB staining, pancreas sections were
digitally rendered using a ScanScope CS digital slide scanner (Aperio Tech-
nologies, Vista, CA) and analyzed using the ImageScope positive pixel count,
version 9 algorithm (Aperio Technologies).
Perifusion. Equal volumes of human islets or stage 6 hES cell–derived cells
were loaded into temperature-/CO2-controlled chambers of an Endotronics
Acu-syst S Perifusion apparatus. HEPES-buffered Krebs Ringers Bicarbonate
Buffer (KRBB) containing 0.5% BSA was pumped through the chambers at
350 l/min after a 1-h preincubation under basal conditions. Fractions were
collected every 5 min and assayed for insulin and glucagon via radioimmuno-
assay (Millipore; Billerica, MA).
Animal studies and transplantation of hES cell–derived cells. All
experiments were approved by the University of British Columbia Animal
Care Committee. Male B6.129S7-Rag
Tm1Mom/J mice (stock 2,216) were ob-
tained from the Jackson Laboratories (Bar Harbor, ME) at 8–10 weeks of age.
Mice were maintained on a 12-h light/dark cycle and had ad libitum access to
a standard irradiated diet (PicoLab 20; #5058l PMI International; St. Louis,
MO). Blood glucose and body weight were monitored 2–3 times weekly after
a 4-h morning fast. Blood glucose was measured via the saphenous vein using
a handheld glucometer (Lifescan; Burnaby, BC). Mice were anesthetized with
inhalable isoﬂurane and received transplants of 1.9 million stage 6 hES
cell–derived cells beneath the left kidney capsule. In some cases, transplants
were performed in diabetic mice (blood glucose 18 mmol/l) after treatment
with streptozotocin (STZ; 175 mg/kg). After transplantation, all mice were
treated with oral enroﬂoxacin (Bayer Animal Health. Shawnee Mission, KS)
for 1 week (50 mg/500 ml in drinking water). In diabetic animals a 30-day,
slow-release insulin pellet (LinBit; Linshin Canada; Toronto, ON) was im-
planted subcutaneously to maintain normoglycemia.
In vivo analysis of transplanted cells. Metabolic analyses were performed
in conscious, restrained mice on the indicated days. Details of metabolic
studies can be found in the supplemental data.
RESULTS
Development of an -cell differentiation protocol.
Signiﬁcant advances in the formation of pancreatic endo-
crine cells from hES cells have been recently achieved by
attempting to mimic the natural stepwise development of
the endocrine pancreas in vitro (4–6). Using a similar
stepwise approach, we performed a combination of small
molecule screening and empirical testing of known endo-
crine morphogens to develop a differentiation protocol
leading to the formation of mature -cells (Fig. 1A). To
improve on previous attempts of in vitro endocrine cell
formation, adherent cultures were differentiated under
feeder-free conditions in the absence of FBS. Our protocol
was divided into six distinct stages, mimicking the step-
wise development of endogenous human islets. To specify
the anterior primitive streak region, referred to here as
mesoendoderm, stage 1 cells were cultured in the pres-
ence of Wnt-3A, FGF2, and activin A (10–12). Robust
expression of CD184 (CXCR4), FOXA2, and SOX17 sug-
gested mesoendoderm formation (13–15), (Fig. 1B and
supplementary Fig. S1A and B), whereas low expression
levels of AFP, SOX7, and BRY(T) suggested a lack of
visceral endoderm (16) and mesoderm formation (supple-
mentary Fig. S1A). Promoting ﬁbroblast growth factor
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FIG. 1. Differentiation of hES cells to maturing endocrine cells. A: Schematic representation of 6-stage differentiation protocol, with media and
supplements shown below. B: Representative ﬂuorescence-activated cell sorter analysis of CD184 expression (green line) in hES cells at stage
1 of differentiation protocol; isotype control in red. Percentage values indicate number of cells expressing CD184 in each group. C: GCG and INS
expression as measured by qRT-PCR in hES cells at stages 4–6, and in stage 6 clusters before (S6C) and after (S6C EC) an extended 4-week
culture period. Data are expressed as fold induction versus human islet control; n  3 for each stage of differentiation. Error bars indicate SE.
D: Representative brightﬁeld images of stage 6 hES cells, Stage 6 clusters, and dithizone-stained human islets. Scale bar, 150 m. (A high-quality
color representation of this ﬁgure is available in the online issue.)
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hedgehog (SHH) and BMP signaling can specify the pan-
creatic domain from the gut tube (17–20) and may reduce
formation of hepatocytes (21). Furthermore, inhibition of
BMP signaling can promote the formation of endocrine
cells in the developing zebraﬁsh (22). Thus, during stages
2 and 3, cells were exposed to FGF7, cyclopamine, retinoic
acid, and Noggin, resulting in the upregulation of foregut
endoderm and pancreatic precursor markers, including
HNF4 and PDX-1 (supplementary Fig. S1C). Removal of
Noggin at later stages of the protocol may allow for
sufﬁcient BMP signaling to facilitate the formation and
maturation of -cells (23).
Disruption of Notch and TGF- signaling has been
shown to promote the pancreatic endocrine cell lineage,
partially through upregulation of NGN3 expression (24)
and by redirecting pancreatic epithelial cells that would
otherwise differentiate into ductal cells toward an endo-
crine fate (25). We performed a targeted screening of 160
cell-permeable kinase inhibitors at stages 3 and 4 of
differentiation and identiﬁed 2-(3-[6-Methylpyridin-2-yl]-
1H-pyrazol-4-yl)-1,5-naphthyridine (ALK5 inhibitor II) as a
potent inducer of insulin and glucagon message (supple-
mentary Fig. S2A and C), likely via upregulation of the
transcription factors NeuroD and NGN3 (supplementary
Figs. S1D and S2B, D, and E). Similar results were ob-
tained using [3-(Pyridin-2-yl)-4-(4-quinonyl)]-1H-pyrazole
(ALK5 inhibitor I), although the upregulation of these
markers was not as dramatic (data not shown). Addition
of the notch inhibitor DAPT at stage 4 resulted in a small
increase in expression of NeuroD and NGN3 expression,
but no signiﬁcant effect on the expression of insulin and
glucagon (data not shown). Thus, in stage 4, inhibition of
TGF- signaling using ALK5 inhibitor II, as well as Notch
signaling using DAPT, progressed cells to a pancreatic
endocrine phenotype. The endocrine cell markers PAX4,
PAX6, and NKX2.2 were highly upregulated at stage 4
(supplementary Fig. S1C) as were the number of NGN3-
positive cells within the culture (supplementary Fig. S2E).
Furthermore, ALK5 inhibitor II resulted in a concentra-
tion-dependent increase in expression of the -cell–en-
riched transcription factor ARX (supplementary Fig. S2D)
thus potentially contributing to the eventual maturation of
the cells toward an -cell phenotype. As further evidence
of the transition of the differentiating cells away from a
-cell phenotype, NKX6.1 message was undetectable in
the differentiating cell population (supplementary Fig.
S1C) and we were unable to detect NKX6.1 immunoﬂuo-
rescence in PDX-1-positive cells within the culture at this
stage (supplementary Fig. S1E). Previous reports have
shown that NKX6.1 null mice lack pancreatic -cells (26),
and as early as 10 weeks of gestation and in the adult
human islet, expression of NKX6.1 becomes limited to
-cells and is absent from glucagon-expressing -cells
(27).
The expression of both glucagon (GCG) and insulin
(INS) was upregulated at stage 5, with continued inhibi-
tion of TGF- receptor signaling (Figs. 1C and supplemen-
tary Fig. S2C). During stage 6, we observed the
spontaneous formation of clusters that resembled human
islets in both size and shape (Fig. 1D). These clusters
contained signiﬁcantly higher levels of INS and GCG
mRNA compared with stage 6 cells that remained part of
the monolayer (Fig. 1C) and were highly enriched for the
panendocrine cell marker synaptophysin (Fig. 2A). In
contrast to adult human islets (Fig. 2B), signiﬁcant coex-
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FIG. 2. Morphologic characterization of hES cell–derived cells. A:
Representative ﬂow analysis of synaptophysin expression in isolated
human islets (left) and stage 6 clusters (right). Isotype shown in red.
B: Representative glucagon (GCG) and insulin (INS) immunoﬂuores-
cence images in parafﬁn-sectioned adult human islets (left) and ﬂow
data from dispersed adult human islets (right). GCG immunoreactivity
is shown in green and INS immunoreactivity is shown in red. Scale bar,
50 m. Quadrant gates set using isotype controls (not shown). C:
Representative GCG and INS immunoﬂuorescence images in parafﬁn-
sectioned stage 6 clusters (left) and ﬂow data from dispersed stage 6
clusters (right). GCG immunoreactivity is shown in green and INS
immunoreactivity is shown in red. Cells expressing both GCG and INS
are shown in yellow. Scale bar, 50 m. Images in B and C include a
DAPI nuclear stain (blue). Quadrant gates set using isotype controls
(not shown). D: Representative GCG and INS ﬂow data from dispersed
stage 6 clusters after an extended 4-week culture period. Quadrant
gates set using isotype controls (not shown). E: Representative syn-
aptophysin expression in stage 6 clusters dispersed after an extended
4-week culture period. Isotype shown in red. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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ﬂow cytometry and immunoﬂuorescence (Fig. 2C). Colo-
calization of C-peptide and insulin immunoreactivities
(supplementary Fig. S3A and B) indicates that the ob-
served insulin immunoreactivity is unlikely to be caused
by uptake of insulin from the culture medium. In stage 6,
cells within the clusters expressed additional islet hor-
mones, including somatostatin and ghrelin (supplemen-
tary Fig. S3C and D). Glucagon-positive cells exhibited a
subcellular morphology similar to that of human -cells
(supplementary Fig. S3E and F).
In vitro characterization of differentiated cells. Glu-
cagon and insulin protein content were 10-fold higher
and 10-fold lower in the stage 6 clusters than in human
islets, respectively (Fig. 3A). Biologically active glucagon
secretion was ﬁrst detected at stage 5 and increased in
stage 6 (Fig. 3B). Stage 6 clusters exhibited insulin secre-
tion in response to KCl, and arginine, albeit at quite low
levels (Fig. 3D), with no signiﬁcant response to glucose
(Fig. 3D). In some cases, basal secretion of glucagon in
low glucose was signiﬁcantly greater than that observed in
human islets (Fig. 3C), although in some cases, basal
glucagon secretion was similar (Fig. 3E). Both KCl and
arginine stimulated glucagon secretion (Fig. 3C and E)a s
did the acetylcholine analog carbachol (Fig. 3E). Glucagon
release was diminished in the presence of the somatosta-
tin analog octreotide or high glucose, suggesting that
glucagon secretion can be physiologically regulated in
these cells (Fig. 3E). After extended culture of stage 6
clusters in vitro, the percentage of insulin-positive and
insulin/glucagon copositive cells decreased markedly.
Conversely, the percentage of glucagon-positive cells was
increased (Fig. 2D), whereas the proportion of cells ex-
pressing the endocrine marker synaptophysin remained
high at 75% (Fig. 2E).
In vivo characterization of differentiated cells. To test
whether stage 6 clusters were lineage-restricted to become
-cells and to assess the physiologic regulation of gluca-
gon secretion from these cells, normoglycemic B6.129S7-
Rag
Tm1Mom/J mice were transplanted with 1.9  10
6
stage 6 clusters. Animals were followed with routine blood
glucose tracking and additional metabolic tests for up to 5
months after transplantation. Cell recipients showed oc-
casionally elevated 4-h fasted blood glucose levels com-
pared with control animals (Fig. 4A). At 99 days after
transplant, prolonged (16 h) fasting resulted in elevated
plasma glucagon levels in cell recipients (399.2  32.5
pg/ml) compared with control animals, where glucagon
levels were largely undetectable (	40 pg/ml). Feeding
signiﬁcantly reduced plasma glucagon to 227.7  46.3
pg/ml in cell transplant recipients (Fig. 4B). Importantly,
postprandial blood glucose levels were not signiﬁcantly
different between groups (Fig. 4B).
We tested the ability of the engrafted hES cell–derived
glucagon-expressing cells to respond to known -cell
secretion stimuli. In response to an intraperitoneal argi-
nine bolus performed at 62 days after transplant, plasma
glucagon levels in cell recipients rose signiﬁcantly from
88.1  15.3 pg/ml to 1,060.4  83.6 pg/ml. In contrast,
control animals mounted a minimal glucagon response to
this challenge (Fig. 4D; 	40 pg/ml at basal to 46.7  4.4
pg/ml at 7 min). Despite the robust glucagon secretion
observed in cell recipients, blood glucose levels increased
only minimally by 13.8  6.9% within the ﬁrst 7 min after
arginine administration. Control animals exhibited a
47.6  15.9% increase in blood glucose levels in this same
timeframe (Fig. 4C). In addition, cell recipients exhibited a
more marked reduction in blood glucose levels at later
time points than control animals, reaching a minimum of
58.7  7.7% of basal vs. 71.4  9.0% of basal for controls at
30 min postinjection. Pancreatic insulin secretion was not
signiﬁcantly different between groups (Fig. 4C, inset).
Interestingly, plasma glucagon-like peptide-1 (GLP-1)
levels were signiﬁcantly elevated in cell recipients after
arginine administration (54.2  8.2 pg/ml vs. 7.5  0.89
pg/ml in control animals at 7 min (supplementary Fig.
S4A). GLP-1 secretion was stimulated by feeding in both
groups. However, although basal plasma GLP-1 levels
were higher in cell recipients, stimulated levels remained
in the physiologic range and were not signiﬁcantly differ-
ent from control animals (supplementary Fig. S4B).
In response to an oral glucose challenge performed at 77
days after transplant, no differences were observed in
peak blood glucose, glucose clearance, or insulin secre-
tion between groups (Fig. 4E). To test whether chronic
hyperglucagonemia in cell transplant recipients induced
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as indicated. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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traperitoneal glucagon tolerance test at 92 days after
transplant. Control mice exhibited a signiﬁcant increase
(45.5  8.9%) in blood glucose at 7 min, although cell
recipients did not (Fig. 4F). However, both groups of mice
mounted an equal pancreatic insulin response (Fig. 4F,
inset). Furthermore, although blood glucose had returned
to basal in control mice by 30 min (101.3  19.5% of basal),
cell recipients exhibited an exaggerated decline in blood
glucose levels at 30 min (65.0  8.4% of basal; Fig. 4F). At
114 days after transplant, control and cell recipient mice
displayed similar insulin sensitivity (Fig. 4G), and both
groups exhibited a robust hypoglycemia-induced increase
in plasma glucagon levels (368.9  128.2 pg/ml for con-
trols, n 
 5; 483.2  106.8 pg/ml for cell recipients; n 
 7;
Fig. 4H, left) in response to a similar level of hyperinsu-
linemia (Fig. 4H, right). Thus, the primary metabolic
phenotype observed in cell recipients was chronic hyper-
glucagonemia together with mild glucagon resistance.
Characterization of engrafted hES-derived cells. At
4 months after transplant, engrafted cells were har-
vested and characterized in comparison with pretrans-
plant stage 6 clusters. Gross histologic analysis of the graft
revealed that most of the cells express glucagon (Fig. 5A).
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FIG. 4. Transplantation of hES cell–derived cells induces hyperglu-
cagonemia and glucagon intolerance. A: Blood glucose levels after a 4-h
morning fast. B: Blood glucose and plasma glucagon levels after an
overnight fast and after 45-min refeeding period at 99 days after
transplant (Tx). Glucagon was below the level of detection for control
and human islet Tx groups (<40 pg/ml). C: Blood glucose and plasma
mouse insulin levels (mINS; inset) at day 62 after transplant in
response to intraperitoneal arginine injection (2 g/kg). D: Plasma
glucagon levels for intraperitoneally arginine test shown in panel C. E:
Blood glucose and plasma mouse insulin levels (mINS; inset) after a 4-h
morning fast at day 77 after transplant in response to oral glucose
challenge (2 g/kg). F: Blood glucose and plasma mouse insulin levels
(mINS; inset) at day 92 after transplant in response to intraperitoneal
glucagon injection (1 g/kg). G: Whole body insulin sensitivity was
assessed by injecting recombinant human insulin (0.4 units/kg) at day
114 after transplant. H: Plasma immunoreactive glucagon (left) and
insulin (right) levels in response to insulin injection shown in panel G.
n  5–7 animals/group; *P < 0.05, **P < 0.01, ***P < 0.001 vs. control;
#P < 0.05 vs. respective 0-min time point (Student t test). N.D., not
detected. (A high-quality color representation of this ﬁgure is avail-
able in the online issue.)
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FIG. 5. Gross histology of transplanted hES cell–derived cells. Grafts
were harvested from hES cell recipients at day 125 after transplant. A:
Representative image of engrafted kidney section after DAB staining
for glucagon. Scale bar  1 mm. B: Representative images of hematox-
ylin-eosin staining at (left) low and (right) high magniﬁcation. Scale
bars  1 mm for low magniﬁcation image and 50 m for high magniﬁ-
cation image. C: Representative images of Masson’s trichrome staining
at (left) low and (right) high magniﬁcation. Collagen ﬁbers are stained
in blue. Scale bars  100 m. In all panels, white dotted line delineates
kidney-graft border. (A high-quality color representation of this ﬁgure
is available in the online issue.)
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crine cell morphology within the graft, whereas Masson’s
trichrome staining indicated that areas not occupied by
glucagon-positive cells were largely occupied by connec-
tive tissue (Fig. 5B–C). As in stage 6 clusters that under-
went extended in vitro culture, transplanted cells lost
insulin expression while maintaining robust glucagon ex-
pression (Fig. 6A). This loss of polyhormonal islet endo-
crine cells is also observed in the developing human
pancreas (28).
The transcription factor ARX is critical for the develop-
ment and maintenance of the -cell phenotype (29,30).
ARX immunoreactivity was extensive within the stage 6
clusters and the transplanted cells (Fig. 6B). Despite
evidence of insulin immunoreactivity within the stage 6
clusters, nuclear-localized PDX-1 immunoreactivity was
not observed in stage 6 clusters and was completely
absent within the graft (Fig. 6C). Furthermore, glucagon
expression in the grafts was colocalized with the prohor-
mone processing enzyme PC2 (Fig. 6D), which mediates
glucagon release from the proglucagon precursor in en-
dogenous -cells, but not with the alternate processing
enzyme PC1/3. The lineage fate of stage 6 clusters was not
dependent on the glycemic state of the animal, as clusters
transplanted into streptozotocin-induced diabetic animals
also developed an -cell phenotype. As such, these cells
were unable to reverse hyperglycemia (supplementary Fig.
S5A) but were capable of arginine-stimulated glucagon
secretion (supplementary Fig. S5B and C). Moreover,
these engrafted cells likewise lost insulin while maintain-
ing glucagon expression (supplementary Fig. S5D). To
further characterize the hES cell–derived cells within the
graft, mRNA expression levels of 84 genes were assessed
in grafts collected 5 months after transplant and com-
pared with adult human islets (supplementary Table S1).
In agreement with immunostaining observations, GCG and
ARX mRNA levels in the engrafted cells were upregulated
37.14  3.51 and 82.53  10.09-fold, respectively, whereas
INS message was nearly undetectable. Interestingly,
MAFA mRNA was downregulated 40.53  2.32-fold and
NKX6.1 message was undetectable, providing further ev-
idence of -cell formation.
Tumorigenicity remains a major concern facing hES
cell–based therapies, and previous studies have shown
that transplantation of endocrine precursor cells can re-
sult in teratoma formation in a signiﬁcant percentage of
examined grafts (8). To test the proliferative potential of
our transplanted hES cells, we examined PCNA immuno-
reactivity within the stage 6 clusters and the engrafted
kidney. Although no features of teratomas or other tumors
were observed in any of the 12 examined engrafted
kidneys (Fig. 5A–C), proliferating cells were observed
within the clusters both before and after transplantation
(Fig. 6E).
To assess whether bioactive glucagon release from the
transplanted cells had reduced the demand for pancreatic
glucagon, pancreatic -cell mass was quantiﬁed. We noted
a signiﬁcant decrease in -cell mass in cell recipients
(241  35 g/pancreas; n 
 6) versus control animals
(393  57 g/pancreas; n 
 5; supplementary Fig. S6).
DISCUSSION
The developmental program driving the formation of ma-
ture endocrine islets, especially in humans, is not fully
understood. A number of critical signaling pathways and
transcription factors have been identiﬁed and their roles
elucidated through genetic knockout and pharmacologic
activation/inhibition experiments; however, the temporal
and spatial cues that result in proper development are
complex. For example, although inhibition of BMP signal-
ing in the early mouse embryo increases Pdx-1 and Hnf6
expression at the expense of liver-speciﬁc genes, inhibi-
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FIG. 6. The -cell phenotype is enriched after in vivo transplantation.
Double immunoﬂuorescence was performed on pretransplant stage 6
clusters and grafts collected 125 days after transplantation. Represen-
tative images are shown. A: Insulin (INS; red) expression is largely lost
after transplantation whereas glucagon (GCG; green) expression pre-
dominates. B: GCG (green) and ARX (red) coexpression is maintained
in stage 6 hES cell–derived cells before and after transplantation. C:
PDX-1 (red) expression is distinct from glucagon (green) expression in
stage 6 clusters, and is absent in grafts. D: Coexpression of glucagon
(green) and PC2 (red) is increased in retrieved grafts compared with
stage 6 clusters. E: Robust PCNA immunoreactivity (red) is observed
in many glucagon-positive cells (green) in stage 6 clusters and after
transplantation (see arrows). Scale bars, 100 m. Images include a
DAPI nuclear stain (blue). Kidney and graft tissues are denoted by K
and G, respectively, in panels B and C. (A high-quality color represen-
tation of this ﬁgure is available in the online issue.)
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Pdx-1 and Hnf6 expression (21). Despite this temporal
complexity, signiﬁcant progress has recently been made in
the differentiation of hES cells to deﬁnitive endoderm
(2,3). This has facilitated the development of protocols
that promote further differentiation to endocrine precur-
sor cell types (4,8). Here we report the formation of
mature glucagon-secreting -cells from hES cells. Charac-
terizing expression levels of several endocrine cell mark-
ers at each stage of differentiation aided in the discovery of
culture conditions that resulted in the efﬁcient formation
of pancreatic endocrine cells. Indeed, this protocol re-
sulted in 75% of differentiated cells expressing the endo-
crine marker synaptophysin. Lineage speciﬁcation toward
-cells was determined by positive immunoreactivity using
an antibody speciﬁc for fully processed glucagon and by
using a cell-based bioassay that recognizes activation of
the human glucagon receptor. The observation that stage 6
clusters matured to -cells in vitro and in vivo, regardless
of the glycemic state of the cell recipient, suggests that
lineage speciﬁcation likely occurs at or before this stage of
the differentiation protocol. Therefore, the creation of -
cells from a similar differentiation protocol may require
culture manipulations preceding this last differentiation
stage.
Pancreatic - and -cells likely arise from the same
NGN3-expressing progenitor cell population (31), and the
coexpression of insulin and glucagon within the develop-
ing human and rodent pancreas has been reported by
several groups (28,32). Although one study has suggested
that these dual hormone expressing cells are unlikely to
contribute to the adult -cell or -cell pool, this conclusion
was based on potentially incomplete labeling during lin-
eage tracing of developing - and -cells (33). The exis-
tence of a subpopulation of dual expressing cells
contributing to the mature -cell population in mice
cannot be ruled out based on this study alone, nor does
any evidence exist for the inability of these dual express-
ing cells to contribute to the development of mature
endocrine cells in the human islet. Although the fate of
these dual-expressing cells remains controversial, it is
clear that these cells arise from the same progenitor pool
as the adult unihormonal cells as NGN3 expression is
likely absolutely required for the formation of pancreatic
endocrine cells (34,35). Temporal regulation of NGN3
expression can greatly inﬂuence the -t o-cell ratio, with
early expression preferentially forming  cells (36). Given
the short duration of our differentiation protocol (26 days
through the end of stage 6), subtle changes in the temporal
activation of transcription factors could dramatically alter
the ratio of -t o-cells created. Furthermore, inhibition of
TGF- signaling, which resulted in an upregulation of
NGN3 and ARX expression in our model, has been impli-
cated in shifting the balanced formation of - and -cells
toward a predominately glucagon-positive population (37).
Our data suggest that there exists a narrow competence
window at stage 4 for the inhibition of TGF- signaling to
induce the expression of NGN3 as well as the endocrine
hormones insulin and glucagon, with Alk5 inhibitor II
increasing expression of these genes when added at stage
4 (supplementary Fig. S2A and C), but not at stage 3 (data
not shown) or stage 5 alone.
Downstream of NGN3, the transcription factors PAX4
and ARX are likewise known to play critical roles in the
proper development of the islet. PAX4 deﬁciency results in
an absence of -cells, but a striking increase in the number
of -cells (38). Conversely, ARX-deﬁcient mice show a
dramatic increase in - and -cell formation at the expense
of -cells (29), suggesting that PAX4 and ARX perform
opposing roles in the maturation of endocrine precursors.
Indeed, these two transcription factors have been shown
to inhibit the expression of each other by directly binding
to the promoter region of the opposing transcription factor
(30). Although we observed levels of PAX4 gene expres-
sion during hES cell differentiation that exceed that found
in adult human islets (1.5 fold; supplementary Table S1),
expression of ARX was much more highly upregulated
(82-fold; Table S1), suggesting that the balance of these
two transcription factors is overwhelmingly tipped toward
an -cell phenotype. In this regard, constitutive overex-
pression of PAX4 in differentiating hES cells can improve
the efﬁciency of -cell formation (39), and conditional
expression of PAX4 in endogenous -cells that contain
normal ARX expression levels results in their transdiffer-
entiation to -cells (40). Thus, the high level of ARX
expression coupled with low expression of INS, PDX-1,
and the -cell–speciﬁc transcription factors MafA, PAX4,
and NKX6.1 (26,41) (Fig. S1C), further highlight the
formation of -cells with this protocol.
In the pancreatic -cell, coexpression of proglucagon
with PC2 results primarily in the formation of mature
glucagon. Conversely, in PC1/3-expressing cells, such as
the gastrointestinal L cells, proglucagon is processed to
yield GLP-1, GLP-2, glicentin, and oxyntomodulin. In some
cells in the stage 6 clusters, glucagon immunoreactivity
colocalized with either PC1/3 or PC2, suggesting that any
or all proglucagon-derived peptides may be produced.
Indeed, cell recipients had signiﬁcantly elevated plasma
GLP-1 levels, suggesting that GLP-1 may be secreted from
the engrafted cells. Previous studies have shown that
some early mouse embryonic glucagon-expressing cells
also express PC1/3 and thus likely produce GLP-1, and
some have suggested that production within the develop-
ing islet may be important for mature islet formation (42).
GLP-1 production from the graft may be from a population
of -cells that have yet to mature or form a separate
differentiated cell lineage. The separate development of
glucagon and GLP-1–expressing cells within the graft is
supported by the appropriately opposite regulation of
glucagon and GLP-1 secretion in cell transplant recipients
after feeding. Furthermore, peak plasma GLP-1 levels after
arginine administration were similar at day 9 and day 62,
whereas peak plasma glucagon levels in response to
arginine administration increased fourfold over this time-
frame, suggesting that the GLP-1–producing cells may
have developed by stage 6, whereas glucagon-producing
cells required more time to mature.
In our study, we show that glucagon secretion from
hES-derived cells was increased by fasting and hypoglyce-
mia and diminished by elevated glucose concentrations.
Moreover, as with native -cells, arginine was a potent
stimulant of glucagon secretion both in vitro and in vivo.
Both fasting and fed plasma glucagon levels were signiﬁ-
cantly higher in cell recipients compared with control
animals. Although hypoglycemia induces glucagon secre-
tion in vivo, glucose itself can stimulate glucagon secre-
tion in isolated -cells (43). In both humans and rodents,
insulin plays a key role in regulating glucagon secretion in
vivo (44,45), possibly via creation of a critical microenvi-
ronment in which insulin secreted from the -cells acts on
adjacent -cells to inhibit glucagon secretion. The in-
creased basal glucagon secretion observed in our study
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to a lack of local insulin production. This excessive basal
glucagon secretion likely contributed to the observed
development of mild glucagon resistance in cell recipients.
Despite glucagon resistance, cell recipients maintained
normal glucoregulatory responses to fasting, feeding, and
nutrient administration. Taken together with our bioassay
data conﬁrming that conditioned media from stage 6
clusters activated the glucagon receptor, and our observa-
tions of decreased pancreatic -cell mass in cell recipi-
ents, these data conﬁrm that the glucagon secreted from
hES-derived cells was mature, bioactive, and secreted in
response to physiologic stimuli.
We previously showed that transplantation of -cell–like
TC-1 cells into normoglycemic mice results in chronic
elevation of fasting blood glucose and impaired glucose
tolerance (46). In contrast, recipients of the differentiated
hES cells displayed only occasionally elevated fasting
blood glucose and had normal glucose tolerance, suggest-
ing that hES-derived cells possess more physiologically-
regulated secretion of glucagon than do TC-1 cells. Given
that a lack of suppression of glucagon secretion contrib-
utes to hyperglycemia in individuals with type 2 diabetes
(47), the development of a physiologically regulated hu-
man -cell line may have signiﬁcant utility as a screening
tool for the identiﬁcation of novel therapeutics that sup-
press glucagon secretion.
As the burgeoning ﬁeld of regenerative medicine contin-
ues to mature, a method for the formation of terminally
differentiated, appropriately regulated, nontumorigenic
pancreatic endocrine cells is highly desirable. We demon-
strate here that with appropriate and deﬁned manipulation
of culture conditions, hES cells can be differentiated into
functional -cells. Through a rigorous in vitro and in vivo
characterization, we show that these hES-derived endo-
crine cells secrete biologically active glucagon in response
to known glucagon secretagogues and, importantly, they
are not tumorigenic. There is increasing evidence to
suggest that -cells exhibit a unique plasticity that allows
for their conversion to insulin-producing -cells under
certain conditions. The ectopic expression of pax4 (40) or
ablation of men1 expression (48) in -cells facilitates their
transdifferentiation to -cells. Furthermore, Herrera and
colleagues recently demonstrated that near total -cell
ablation results in the conversion of pre-existing -cells to
-cells (49). In light of these recent ﬁndings, our hES
cell–derived -cells may serve as a novel starting material
for the identiﬁcation of small molecules that promote the
conversion of this cell type to -cells, either in our in vitro
culture system or in vivo. Given that transdifferentiation of
exocrine cells to -cells has been recently demonstrated in
vivo (50), we speculate that it may be possible to identify
compounds that convert -cells to -cells as a novel
strategy for the treatment of diabetes.
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